Discontinued — last reported Q4 '21
Business Segments · Restructuring Reserve
Covance Drug Development — Restructuring Reserve
Labcorp Holdings Covance Drug Development — Restructuring Reserve decreased by 15.6% to $3.80M in Q4 2021 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ4 2014
Last reportedQ4 2021Feb 25, 2022
Rolls up toRestructuring Reserve
How to read this metric
A decreasing balance indicates the completion of restructuring activities and the utilization of the reserve.
Detailed definition
The balance of accrued liabilities set aside to cover future cash outflows related to planned restructuring activities w...
Peer comparison
Standard accounting practice for tracking committed but unpaid restructuring obligations.
Metric ID:
lh_segment_covance_drug_development_restructuring_reserveHistorical Data
3 periods
| Q2 '21 | Q3 '21 | Q4 '21 | |
|---|---|---|---|
| Value | $5.90M | $4.50M | $3.80M |
| QoQ Change | — | -23.7% | -15.6% |
Range$3.80M – $5.90M
Current Streak2+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — restructuring reserve?
- Labcorp Holdings (LH) reported covance drug development — restructuring reserve of $3.80M in Q4 2021.
- What does covance drug development — restructuring reserve mean?
- The remaining liability for planned restructuring costs in the drug development segment.